These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 3877535

  • 1. Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
    Melamed E, Youdim MB.
    Br J Pharmacol; 1985 Nov; 86(3):529-31. PubMed ID: 3877535
    [Abstract] [Full Text] [Related]

  • 2. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE.
    Eur J Pharmacol; 1988 Feb 09; 146(2-3):313-8. PubMed ID: 3131149
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW, Robertson DW, Hemrick-Luecke SK.
    J Pharmacol Exp Ther; 1987 Feb 09; 240(2):415-20. PubMed ID: 3100775
    [Abstract] [Full Text] [Related]

  • 4. Monoamine oxidase B(MAO-B) is the major catalyst for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation in human brain and other tissues.
    Glover V, Gibb C, Sandler M.
    Neurosci Lett; 1986 Feb 28; 64(2):216-20. PubMed ID: 3083305
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK, Sonsalla PK, Heikkila RE.
    J Neurochem; 1987 Mar 28; 48(3):929-34. PubMed ID: 3492590
    [Abstract] [Full Text] [Related]

  • 6. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW, Hemrick-Luecke SK, Perry KW.
    J Pharmacol Exp Ther; 1988 Nov 28; 247(2):531-5. PubMed ID: 3141609
    [Abstract] [Full Text] [Related]

  • 7. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.
    Heikkila RE, Hess A, Duvoisin RC.
    Life Sci; 1985 Jan 21; 36(3):231-6. PubMed ID: 3917525
    [Abstract] [Full Text] [Related]

  • 8. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC.
    Nature; 1985 Jan 21; 311(5985):467-9. PubMed ID: 6332989
    [Abstract] [Full Text] [Related]

  • 9. Astrocytes as a primary locus for the conversion MPTP into MPP+.
    Brooks WJ, Jarvis MF, Wagner GC.
    J Neural Transm; 1989 Jan 21; 76(1):1-12. PubMed ID: 2785159
    [Abstract] [Full Text] [Related]

  • 10. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species.
    Jossan SS, Sakurai E, Oreland L.
    Pharmacol Toxicol; 1989 Mar 21; 64(3):314-8. PubMed ID: 2786198
    [Abstract] [Full Text] [Related]

  • 11. Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease.
    Riachi NJ, Arora PK, Sayre LM, Harik SI.
    J Neurochem; 1988 Apr 21; 50(4):1319-21. PubMed ID: 3258018
    [Abstract] [Full Text] [Related]

  • 12. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW, Hemrick-Luecke SK.
    Life Sci; 1985 Sep 23; 37(12):1089-96. PubMed ID: 3875779
    [Abstract] [Full Text] [Related]

  • 13. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
    Wiener HL, Hashim A, Lajtha A, Sershen H.
    J Neurosci Res; 1989 Jul 23; 23(3):326-9. PubMed ID: 2504936
    [Abstract] [Full Text] [Related]

  • 14. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Melamed E, Rosenthal J, Youdim MB.
    J Neurochem; 1990 Oct 23; 55(4):1427-31. PubMed ID: 2398363
    [Abstract] [Full Text] [Related]

  • 15. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT, Irwin I, Delanney LE, Langston JW.
    J Pharmacol Exp Ther; 1995 May 23; 273(2):716-20. PubMed ID: 7752075
    [Abstract] [Full Text] [Related]

  • 16. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
    Sagi Y, Weinstock M, Youdim MB.
    J Neurochem; 2003 Jul 23; 86(2):290-7. PubMed ID: 12871570
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier.
    Riachi NJ, Harik SI.
    Life Sci; 1988 Jul 23; 42(23):2359-63. PubMed ID: 3259663
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Studies on the interaction of roxindole with brain monoamine oxidases and dopaminergic neurones in vitro and in vivo.
    Seyfried CA, Adam G.
    Pharmacol Toxicol; 1994 Jun 23; 74(6):314-20. PubMed ID: 7937563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.